AbbVie price target lowered to $248 from $251 at BofA

BofA analyst Tim Anderson lowered the firm’s price target on AbbVie (ABBV) to $248 from $251 and keeps a Neutral rating on the shares. While stating that AbbVie reported a “good quarter overall,” the firm thinks the beat-and-raise was “perhaps not by enough,” which it says partly reflects a stock that is “priced for perfection.”